 The FDA has issued a Complete Response Letter CRL regarding Verrica Pharmaceuticals Incs NASDAQ: VRCA marketing application for VP-102 for molluscum contagiosum. The only deficiency listed in the CRL was related to the deficiencies identified at a general reinspection. 